Article
Influence of CYP2C19 polymorphism and concomitant antiepileptic drugs on serum clobazam and N-desmethyl clobazam concentrations in patients with epilepsy.
Therapeutic drug monitoring - 1 Jun 2013
Yamamoto Yoshiaki, Takahashi Yukitoshi, Imai Katsumi, Miyakawa Kou, Nishimura Shigeko, Kasai Risa, Ikeda Hiroko, Takayama Rumiko, Mogami Yukiko, Yamaguchi Tokito, Terada Kiyohito, Matsuda Kazumi, Inoue Yushi, Kagawa Yoshiyuki
Abstract excerpt
OBJECTIVE: The aims of this study were to identify the factors influencing the metabolism of clobazam (CLB) and its active metabolite [N-desmethyl clobazam (NCLB)] and to evaluate the NCLB concentration as an indicator for CYP2C19 polymorphism in epileptic patients. METHODS: A total of 302 serum samples from 238 Japanese patients were evaluated. The ratios of the serum CLB and NCLB concentrations to the CLB dose...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
